Sublingual Immunotherapy (SLIT) for U. S. Naval Hospital Yokosuka, Japan
Cancelled Special Notice Posted
Not the latest version. See the latest pre-solicitation from .
- Solicitation number
- HT941024N0065
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Yokosuka Kagawa Japan
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency Contracting Activity (DHACA) has issued a Special Notice to negotiate and award a firm fixed-price contract for Sublingual Immunotherapy (SLIT) consumables to Allergy Choices, Inc. This sole source contract will support the U.S. Naval Hospital Yokosuka in Japan and provide uninterrupted operational support for the waterfront.
The purpose of this Special Notice is to procure SLIT consumables for the U.S. Naval Hospital Yokosuka. The contract will have a base year and four option years, with a total quantity of 120 vials per year. Allergy Choices, Inc. is the only source that can meet the government's minimum requirements. Interested vendors must submit capability statements by May 16, 2024, demonstrating their ability to provide the required services. The government will determine whether to proceed with the sole source award or conduct a competitive procurement based on the responses received.
Notice text
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to negotiate and award a firm fixed price contract for Sublingual Immunotherapy (SLIT) from Allergy Choices, Inc. in accordance with Federal Acquisition Regulation (FAR) 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to:
Allergy Choices, Inc.
2731 National Dr.
Onalaska, WI 54650-8784
The North American Industry Classification System (NAICS) code for this requirement is 325412 – Pharmaceutical Preparation Manufacturing; the business size standard is 1,300 employees. The Product Service Code (PSC) is 6505 – Drugs and Biologicals.
The US Naval Hospital Yokosuka provides medical readiness for U.S. Pacific Fleet. Having a dedicated contracted SLIT support for US Naval Hospital Yokosuka will allow uninterrupted operational support for the waterfront.
The objective of this sole source award is to procure SLIT consumables (listed below). Allergy Choices, Inc.
doesn’t have distributors for their products and ship directly to consumers.
Consumables:
Item#
Description
QTY (EA)
Ultimate Delivery Date
Base Year
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2025
Option 1
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2026
Option 2
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2027
Option 3
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2028
Option 4
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2029
SHIP TO ADDRESS: US Naval Hospital Yokosuka JAPAN:
US Naval Hospital Yokosuka
Attention : Otolaryngology Department
PSC 475 Box 6
FPO AP 96350-1600
Based on market research, Allergy Choices, Inc., is the only source that can meet the Government’s minimum requirements for the SLIT consumables from Allergy Choices, Inc. at US Naval Hospital Yokosuka
This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required services for US Naval Hospital Yokosuka. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.
If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Marcela Cervantes at marcela.cervantes.civ@health.mil. The closing date for challenges is no later than 11:00 Pacific Time, 16 May 2024.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
Files
| File | Type | Posted |
|---|---|---|
| Notice of Intent to Sole Source - SLIT.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Sublingual Immunotherapy (SLIT) for U. S. Naval Hospital Yokosuka, Japan | Pre-Solicitation | |
| This notice | Special Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity